AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22492697 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin 100 mg/m² day 1 + 5-FU 1000 mg/m² day 1-5) followed by irradiation for complete responders
Number of subjects: 202
Study 22492697 — intervention group
Group type: COMPARATOR
Intervention: Surgical approach (total laryngectomy with partial pharyngectomy and neck dissection, followed by irradiation)
Number of subjects: 202
Study 21235067 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep needling (DN) of ST 25
Number of subjects: 95
Study 21235067 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow needling (SN) of ST 25
Number of subjects: 95
Study 21235067 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Lactulose, 20-30 mL/d)
Number of subjects: 95
Study 18179320 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype threat conditions
Number of subjects: 0
Study 18179320 — intervention group
Group type: EXPERIMENTAL
Intervention: Interracial interactions conceived as learning opportunities
Number of subjects: 0
Study 18179320 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious awareness of stereotype threat
Number of subjects: 0
Study 16873930 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - Prempo (0.625 mg conjugated estrogen and 2.5 mg medroxyprogesterone acetate)
Number of subjects: 98
Study 16873930 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 98
Study 16873930 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 98
Study 12845587 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of stavudine (40 mg)
Number of subjects: 24
Study 12845587 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of stavudine (40 mg)
Number of subjects: 24
Study 10613385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactaid II+
Number of subjects: 8
Study 10613385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactaid 7
Number of subjects: 8
Study 8876577 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of bupivacaine hydrochloride for 72 hours postoperatively
Number of subjects: 21
Study 8876577 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution for 72 hours postoperatively (Control Group)
Number of subjects: 21
Study 8876577 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of bupivacaine hydrochloride
Number of subjects: 21
Study 1676251 — intervention group
Group type: EXPERIMENTAL
Intervention: IMREG-1
Number of subjects: 143
Study 1676251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 225252 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 micrograms + levonorgestrel 250 micrograms (50/250)
Number of subjects: 75
Study 225252 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 micrograms + levonorgestrel 125 micrograms (50/125)
Number of subjects: 75
Study 225252 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 30 micrograms + levonorgestrel 150 micrograms (30/150)
Number of subjects: 75
Study 30391656 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient report of goals-of-care discussion
Number of subjects: 494
Study 30391656 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician report of goals-of-care discussion
Number of subjects: 494
Study 30391656 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR documentation of goals-of-care discussion
Number of subjects: 494
Study 30391656 — intervention group
Group type: COMPARATOR
Intervention: Clinician report and EHR documentation of goals-of-care discussion
Number of subjects: 494
Study 28230252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone 1,500 mg/day
Number of subjects: 147
Study 28230252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 25842384 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 254
Study 25842384 — intervention group
Group type: COMPARATOR
Intervention: Health information control
Number of subjects: 254
Study 23863208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon + Lamivudin for 48 weeks
Number of subjects: 647
Study 23863208 — intervention group
Group type: COMPARATOR
Intervention: Lamivudin + Placebo for 48 weeks
Number of subjects: 647
Study 20682597 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg)
Number of subjects: 21
Study 20682597 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 21
Study 20682597 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 21
Study 19441604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and salmeterol combination via hydrofluoroalkane metered-dose inhaler
Number of subjects: 725
Study 19441604 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol alone
Number of subjects: 725
Study 19441604 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate alone
Number of subjects: 725
Study 19441604 — intervention group
Group type: COMPARATOR
Intervention: Placebo via traditional chlorofluorocarbon metered-dose inhaler
Number of subjects: 725
Study 17242269 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging-guided percutaneous core needle biopsy
Number of subjects: 125
Study 16858238 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal cardioversion (TOC) with a step-up protocol of 30, 50, 70 and 100 J
Number of subjects: 210
Study 16858238 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic cardioversion (TTC) with a step-up protocol of 70, 100, 120 and 150 J
Number of subjects: 210
Study 14654643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact, circuit-based, jumping intervention (10 minutes, 3 times a week) over 2 school years
Number of subjects: 32
Study 10418886 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-session face-to-face intervention emphasizing abstinence and safer sex
Number of subjects: 515
Study 7487795 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32
Study 7487795 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 32
Study 1706903 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. injection of 0.5 ml 'Influmun' vaccine from SSW Dresden/GDR
Number of subjects: 350
Study 1706903 — intervention group
Group type: COMPARATOR
Intervention: enteric-wated capsules containing approximately 60 micrograms hemagglutinin of all three virus strains
Number of subjects: 350
Study 86665 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical treatment
Number of subjects: 768
Study 86665 — intervention group
Group type: COMPARATOR
Intervention: medical treatment
Number of subjects: 768
Study 28691550 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP) therapy for OCD, 4 weeks duration
Number of subjects: 44
Study 28691550 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 44
Study 27780630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap administered 3-4 weeks before PCV13 and MCV4 (Group A)
Number of subjects: 111
Study 27780630 — intervention group
Group type: COMPARATOR
Intervention: All three vaccines administered on the same day (Group B)
Number of subjects: 111
Study 27780630 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 and MCV4 administered 3-4 weeks before Tdap (Group C)
Number of subjects: 111
Study 23932933 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3mgkg(‐1) BW)
Number of subjects: 9
Study 23932933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 22077933 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stretch compression (SSB)
Number of subjects: 321
Study 22077933 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer compression bandaging (4LB)
Number of subjects: 321
Study 22077933 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 321
Study 20562669 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lenses
Number of subjects: 484
Study 20562669 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 484
Study 17968381 — intervention group
Group type: EXPERIMENTAL
Intervention: Third weight fluctuation tertile
Number of subjects: 3553
Study 17968381 — intervention group
Group type: EXPERIMENTAL
Intervention: No weight fluctuations
Number of subjects: 3553
Study 17968381 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight fluctuations (WF)
Number of subjects: 3553
Study 17968381 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain during follow-up
Number of subjects: 3553
Study 17968381 — intervention group
Group type: EXPERIMENTAL
Intervention: MS components (raised blood pressure, low HDL-cholesterol, increased waist circumference)
Number of subjects: 3553
Study 17057785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating occlusion (full-time and symmetric for no amblyopia, asymmetric for amblyopia)
Number of subjects: 44
Study 17057785 — intervention group
Group type: COMPARATOR
Intervention: No occlusion
Number of subjects: 44
Study 12701653 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind/body intervention (6-week program with 6 sessions of 90 minutes each)
Number of subjects: 128
Study 12701653 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 128
Study 10394962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (1,500 mg/m2 over 5 days intravenously)
Number of subjects: 20
Study 10394962 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (100-200 mg/m2 over 5 days orally)
Number of subjects: 20
Study 8775039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 70
Study 8775039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 2148150 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times daily for 4 weeks
Number of subjects: 19
Study 2148150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6996931 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg dipyrone
Number of subjects: 299
Study 6996931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 6996931 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg paracetamol
Number of subjects: 299
Study 31260565 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOCHIP test for bullous pemphigoid (BP)
Number of subjects: 69
Study 31260565 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOCHIP test for pemphigus foliaceus (PF)
Number of subjects: 69
Study 31260565 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOCHIP test for pemphigus vulgaris (PV)
Number of subjects: 69
Study 31260565 — intervention group
Group type: COMPARATOR
Intervention: Direct immunofluorescence (DIF)
Number of subjects: 69
Study 31260565 — intervention group
Group type: COMPARATOR
Intervention: Indirect immunofluorescence (IIF)
Number of subjects: 69
Study 31260565 — intervention group
Group type: COMPARATOR
Intervention: ELISA
Number of subjects: 69
Study 31342823 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction during dressing change plus standard pharmacological analgesic intervention
Number of subjects: 182
Study 31342823 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological analgesic intervention during dressing change
Number of subjects: 182
Study 28708873 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cART for two years
Number of subjects: 19
Study 24938927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic compression belt
Number of subjects: 49
Study 24938927 — intervention group
Group type: COMPARATOR
Intervention: No pelvic compression belt
Number of subjects: 49
Study 23388358 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified WHO hand rub formulations with higher alcohol concentration (5% increase) and lower glycerol concentration (0.725%)
Number of subjects: 25
Study 23388358 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified WHO hand rub formulations without glycerol
Number of subjects: 25
Study 23388358 — intervention group
Group type: COMPARATOR
Intervention: Reference hand antisepsis procedure
Number of subjects: 25
Study 20980992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0, 10, 20, 40, and 60 mg/70 kg)
Number of subjects: 18
Study 20980992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone (Bup/Nx; 2/0.5, 8/2, and 16/4 mg/day)
Number of subjects: 18
Study 20980992 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 18
Study 18544181 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 687
Study 17103296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of resistance and balance-jumping training (COMB)
Number of subjects: 149
Study 17103296 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 149
Study 17103296 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance-jumping training (BAL)
Number of subjects: 149
Study 17103296 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at least twice a week in COMB group
Number of subjects: 149
Study 17103296 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 149
Study 15312856 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 407
Study 15312856 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 407
Study 15312856 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PCI and CABG
Number of subjects: 407
Study 10858838 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam coinduction (0.05 mg/kg BW midazolam, 2.5 micrograms/kg BW fentanyl, 1.0 mg/kg BW propofol)
Number of subjects: 40
Study 10858838 — intervention group
Group type: COMPARATOR
Intervention: Control group (2.5 micrograms/kg BW fentanyl and 2.0 mg/kg BW propofol)
Number of subjects: 40
Study 10858838 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam coinduction
Number of subjects: 40
Study 9350069 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately salt-restricted diet (5 capsules of placebo)
Number of subjects: 16
Study 9350069 — intervention group
Group type: COMPARATOR
Intervention: Salt-supplemented group (5 capsules of 10 mmol sodium per capsule)
Number of subjects: 16
Study 8462079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3.15 g omega-3 fatty acids)
Number of subjects: 212
Study 8462079 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 212
Study 2951407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 30
Study 2951407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30391581 — intervention group
Group type: EXPERIMENTAL
Intervention: Test n Treat (TnT) intervention
Number of subjects: 509
Study 30391581 — intervention group
Group type: COMPARATOR
Intervention: Control (no TnT)
Number of subjects: 509
Study 29617940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) access
Number of subjects: 60
Study 29617940 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) access
Number of subjects: 60
Study 27655438 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D3 supplements/d for 20 weeks
Number of subjects: 110
Study 27655438 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg vitamin D3 supplements/d for 20 weeks
Number of subjects: 110
Study 27655438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 μg vitamin D3 supplements/d for 20 weeks)
Number of subjects: 110
Study 27655438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake to maintain 25(OH)D concentrations >25 nmol/L
Number of subjects: 110
Study 27655438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake to maintain 25(OH)D concentrations >30 nmol/L
Number of subjects: 110
Study 27655438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake to maintain 25(OH)D concentrations >40 nmol/L
Number of subjects: 110
Study 27655438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake to maintain 25(OH)D concentrations >50 nmol/L
Number of subjects: 110
Study 24702663 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids N Fitness(©) program
Number of subjects: 251
Study 22453571 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 62154
Study 20041414 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackcurrant oil soft capsule (BOSC) 1.8 g b.i.d. every day for 6 weeks
Number of subjects: 2154
Study 20041414 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackcurrant oil soft capsule (BOSC)
Number of subjects: 2154
Study 19143245 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular intraoperative injection of multimodal analgesic drugs
Number of subjects: 76
Study 19143245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 76
Study 15816106 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately accelerated radiotherapy (5 vs. 6 fx/wk)
Number of subjects: 803
Study 12415026 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment 0.1 IU/kg/d subcutaneously at bedtime for 2 months
Number of subjects: 12
Study 12415026 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 2 months
Number of subjects: 12
Study 12415026 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 12
Study 10754618 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine 20 min infusion
Number of subjects: 12
Study 10754618 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine 24 h infusion
Number of subjects: 12
Study 8771866 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐1,3‐D‐glucan gel
Number of subjects: 20
Study 8771866 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 1474987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenticonazole powder (antifungal treatment)
Number of subjects: 30
Study 1474987 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control treatment)
Number of subjects: 30
Study 6726012 — intervention group
Group type: EXPERIMENTAL
Intervention: HLI (Human leukocyte interferon) ophthalmic drops (2.4 x 10^6 IU/ml, 50,000 units per drop, administered two times a day for five days)
Number of subjects: 15
Study 6726012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (commercial artificial tear solution)
Number of subjects: 15
Study 31186260 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session educational intervention tailored for ethnic- and gender-specific groups to increase men's social support for their female partners to receive a Pap test.
Number of subjects: 0
Study 31186260 — intervention group
Group type: COMPARATOR
Intervention: Preexisting brochures on Pap testing (for women) or general men's health (for men)
Number of subjects: 0
Study 29121283 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 174
Study 29121283 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 174
Study 26064048 — intervention group
Group type: EXPERIMENTAL
Intervention: AOM 400 (400 mg once-monthly)
Number of subjects: 662
Study 26064048 — intervention group
Group type: COMPARATOR
Intervention: Oral aripiprazole (10-30 mg/d)
Number of subjects: 662
Study 26064048 — intervention group
Group type: COMPARATOR
Intervention: AOM 50 mg (subtherapeutic dose)
Number of subjects: 662
Study 23796315 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy
Number of subjects: 97
Study 23796315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure group therapy
Number of subjects: 97
Study 23796315 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 97
Study 21456040 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-enhanced habit reversal treatment (HRT)
Number of subjects: 10
Study 18663543 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric banding surgery (LGBS)
Number of subjects: 34
Study 18663543 — intervention group
Group type: COMPARATOR
Intervention: Normal weight controls
Number of subjects: 34
Study 16453051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral crystalline cyanocobalamin (1,000 microgram per day for at least 1 month)
Number of subjects: 20
Study 12910570 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine (alone and in combination with chondroitin)
Number of subjects: 0
Study 12910570 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 0
Study 12910570 — intervention group
Group type: COMPARATOR
Intervention: Chondroitin
Number of subjects: 0
Study 12910570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11502782 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/d oral L-carnitine
Number of subjects: 50
Study 11502782 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d oral L-carnitine
Number of subjects: 50
Study 11502782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11502782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density
Number of subjects: 50
Study 9422900 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone knee‐chest position with 3 ml of 0.5% bupivacaine
Number of subjects: 40
Study 9422900 — intervention group
Group type: COMPARATOR
Intervention: Supine side horizontal position with 3 ml of 0.5% bupivacaine
Number of subjects: 40
Study 9422900 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone knee‐chest position
Number of subjects: 40
Study 9422900 — intervention group
Group type: COMPARATOR
Intervention: Supine side horizontal position
Number of subjects: 40
Study 9422900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8124913 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 intravenous pulses of 1000 mg methylprednisolone (MP) on alternate days during the first week
Number of subjects: 30
Study 8124913 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 oral pulses of 100 mg prednisolone
Number of subjects: 30
Study 8124913 — intervention group
Group type: COMPARATOR
Intervention: No additional corticosteroids
Number of subjects: 30